ReviewAdvances in therapy2025
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.
Review in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of diabetes has seen significant advancements with the introduction of various injectable therapies. Being a common chronic disorder, it is managed by doctors across all specialties worldwide. Despite the availability of new medications, healthcare professionals continue to face ambiguity due to differing terminologies and variations in regional practices. This review aims to elucidate the current therapeutic spectrum of injectable therapies in diabetes care, providing clarity on the types, mechanisms, and clinical implications of both insulin and non-insulin injections. An extensive review of existing literature was conducted, focusing on insulin injections (including short-acting, rapid-acting, ultra-rapid acting, intermediate-acting, long acting and ultra-long-acting types), non-insulin injections (such as glucagon-like peptide-1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] agonist, and amylin analogs) and co-formulations (long-acting insulin with GLP-1 or long-acting insulin with rapid acting insulin). We have included innovators and biosimilars in this review article for better understanding. Insulin therapies offer tailored glycemic control, while non-insulin injectables provide additional benefits in weight management and reduced hypoglycemia risk. This review serves as a comprehensive guide for healthcare providers worldwide to navigate the landscape of injectable treatment options in diabetes, with a focus on optimizing therapeutic outcomes through informed decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.